G

Gimv

164 employees

Gimv is a European private equity firm that invests in selected investment platforms with a focus on Benelux, France, and Germany.

Investor insights

Countries invested in

united kingdom1
united states1

Sectors invested in

Biotechnology40
Health Care39
Manufacturing21
Medical Device18
Software18
Therapeutics14
Medical13
Biopharma12
Information Technology12
Enterprise Software8
Pharmaceutical8
antibodies6
oncology6
Electronics6
Hardware6
Web Development6
Computer5
Energy5
Simulation4
Machine Learning4

Funding rounds participated in

$17M sweet spot round size

Most of their 167 investments are in rounds between $10M and $32M

Investor type

Private Equity Firm
Venture Capital

Basic info

Industry

financial services

Sectors

Smart Industries
Growth capital
Finance
Buy-and-Build
Venture Capital
Consumer
Sustainable Cities
Life Sciences
Active investor
Financial Services
Healthcare
Building Leading Companies

Date founded

1980

Investments made

E

ERS electronic GmbH raised undisclosed on June 1, 2023

Investors: Gimv

C

Complement Therapeutics raised $79M on April 17, 2023

Investors: Hadean Ventures, Forbion, PANAKES, BGV (BioGeneration Ventures), Cambridge Innovation Capital plc, Seroba-Kernel Ltd (Ireland) and Gimv

M

Mediar Therapeutics raised $85M on March 15, 2023

Investors: Pureos Bioventures, Mission BioCapital, Bristol-Myers Squibb, UK, Sofinnova Partners and Gimv

F

FIRE1 Foundry raised $25M on March 15, 2023

Investors: Novo Holdings, Gilde Healthcare, Andera Partners, Lightstone Ventures, National Treasury Management Agency and Gimv

P

Paleo raised $13M on February 21, 2023

Investors: SFPI-FPIM, Planet A Ventures, DSM Venturing, Siddhi Capital, Beyond Impact VC and Gimv

J

JenaValve Technology, Inc. raised $100M on August 31, 2022

Investors: 沛嘉医疗科技(苏州) 有限公司, Qatar Investment Authority, -, Innovatus Capital Partners and Gimv

I

Imcheck Therapeutics raised $100M on June 13, 2022

Investors: Pureos Bioventures, The Invus Group, Earlybird Venture Capital, Eurazeo, The Leukemia & Lymphoma Society, Wellington Partners, EQT Life Sciences and Gimv

I

ImmunOs Therapeutics AG raised $73M on June 7, 2022

Investors: GL Capital Group, PEAK6, Samsara BioCapital, Mission BioCapital, Redalpine, Lightspeed Venture Partners and Gimv

B

BioConnection B.V. raised undisclosed on April 22, 2022

Investors: Mibiton Foundation and Gimv

P

Precirix raised $88M on March 16, 2022

Investors: Pontifax Venture Capital, Inkef, HealthCap, Novo Holdings, V-Bio Ventures, BioMedPartners, Forbion and Gimv

FAQ